key: cord-274284-mi4n7xty
authors: Pang, Khang Wen; Chee, Jeremy; Subramaniam, Somasundaram; Ng, Chew Lip
title: Frequency and Clinical Utility of Olfactory Dysfunction in COVID-19: a Systematic Review and Meta-analysis
date: 2020-10-13
journal: Curr Allergy Asthma Rep
DOI: 10.1007/s11882-020-00972-y
sha: 
doc_id: 274284
cord_uid: mi4n7xty

BACKGROUND: Olfactory dysfunction (OD) has been gaining recognition as a symptom of COVID-19, but its clinical utility has not been well defined. OBJECTIVES: To quantify the clinical utility of identifying OD in the diagnosis of COVID-19 and determine an estimate of the frequency of OD amongst these patients. METHODS: PubMed was searched up to 1 August 2020. Meta-analysis A included studies if they compared the frequency of OD in COVID-19 positive patients (proven by reverse transcription polymerase chain reaction) to COVID-19 negative controls. Meta-analysis B included studies if they described the frequency of OD in COVID-19 positive patients and if OD symptoms were explicitly asked in questionnaires or interviews or if smell tests were performed. RESULTS: The pooled frequency of OD in COVID-19 positive patients (17,401 patients, 60 studies) was 0.56 (0.47–0.64) but differs between detection via smell testing (0.76 [0.51–0.91]) and survey/questionnaire report (0.53 [0.45–0.62]), although not reaching statistical significance (p = 0.089). Patients with reported OD were more likely to test positive for COVID-19 (diagnostic odds ratio 11.5 [8.01–16.5], sensitivity 0.48 (0.40 to 0.56), specificity 0.93 (0.90 to 0.96), positive likelihood ratio 6.10 (4.47–8.32) and negative likelihood ratio 0.58 (0.52–0.64)). There was significant heterogeneity amongst studies with possible publication bias. CONCLUSION: Frequency of OD in COVID-19 differs greatly across studies. Nevertheless, patients with reported OD were significantly more likely to test positive for COVID-19. Patient-reported OD is a highly specific symptom of COVID-19 which should be included as part of the pre-test screening of suspect patients.

Olfactory dysfunction has been gaining increasing recognition in the fight against COVID-19 [1, 2] . What began as anecdotal reports of patients presenting with anosmia as the sole symptom has evolved into changes in clinical case definitions for suspect cases internationally.

In the context of COVID-19 infections, acute olfactory dysfunction (OD) is defined as decreased or altered sense of smell of a duration of 14 days or less, in the absence of chronic rhinosinusitis, a history of head trauma or neurotoxic medications. OD can be associated with flavour (smell + taste) dysfunction. However, COVID-19 may also affect real taste (sweet, salty, bitter, acidic, umami).

OD is estimated to afflict 3-20% of the population [3, 4] . Post-viral anosmia accounts for up to 40% cases of anosmia or which coronaviruses are thought to account for 10-15% of these cases [5, 6] . As such, it is plausible that COVID-19 may cause OD.

Though the exact pathogenesis is unclear, the high rate of recovery of olfactory function within 1-3 weeks after the onset of OD [7] [8] [9] [10] may provide clues on the mechanism and extent of injury to olfactory epithelium and/or neurones. There are two proposed mechanisms by which COVID-19 causes anosmia. Coronaviruses are known to infect olfactory epithelium [11, 12] . Human angiotensin-converting enzyme 2 (ACE-2) receptor, which is a SARS-CoV-2 receptor, is expressed in the olfactory epithelial cells within the olfactory cleft, specifically the sustentacular cells [13, 14] . Inflammation of the olfactory cleft mucosa can cause conductive OD by reducing airflow and hence odorant presentation to the olfactory cleft [15] .

This symptom may hence represent a potential clinical screening tool to facilitate testing of asymptomatic individuals. However, it remains unclear if these findings are causally and uniquely related to COVID-19 infection, or due to increased recognition of OD as a symptom [16] . Amongst patients afflicted with COVID-19, decreased awareness of olfactory dysfunction may be overshadowed by more severe symptoms such as respiratory distress. Furthermore, data in the literature suggests that selfreporting of the sense of smell is specific but not sensitive [17, 18] . Amongst those with measured olfactory dysfunction, 74 .2% did not recognise it [18] . This is so amongst patients afflicted with COVID-19 as well [19•] .

As such, we set out to conduct a systematic review and meta-analysis on OD in COVID-19 to quantify the clinical utility of identifying OD in the diagnosis of COVID-19 and determine an estimate of the frequency of OD amongst these patients. We also aimed to look separately at survey-reported and smell test-reported OD given the reported variance between the two.

The Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) Statement [20] was referenced to structure the study. A study protocol was not registered, and no ethics approval was required.

Studies were eligible if they were indexed on PubMed. The search was performed on 9 May 2020, and the strategy used was "(anosmia OR smell OR hypos* OR olfact*) AND (COVID* OR SARS-CoV-2 OR 2019-nCoV OR coronavirus)." The search was not limited by publication date and there was no language filter applied. The search was updated on 1 August 2020.

Screening of titles and abstracts was performed by 2 independent researchers to determine if the studies met the inclusion criteria. If abstracts were not available, the full text was retrieved and analysed. Any disagreements between the 2 researchers were resolved by discussion and by consulting a third, senior researcher. Data extracted from eligible studies included the author, year of publication, study design, country of origin, OD testing method, COVID-19 testing method and number of cases reporting OD amongst COVID-19 positive and negative patients. Data was entered into Excel sheets independently by the 2 researchers and then compared. Methodological quality was rated independently by two reviewers using the risk of bias tool for prevalence studies by Hoy et al. [21] .

To quantify the clinical utility of identifying OD in the diagnosis of COVID-19, we compared the frequency of OD in patients stratified by COVID-19 test results using the reverse transcription polymerase chain reaction (RT-PCR). This was performed in Meta-analysis A. Studies were included if they compared the frequency of smell disturbance in COVID-19 positive patients (proven by RT-PCR) to COVID-19 negative controls in casecontrol studies. Appropriate controls were defined as patients who were suspected of having COVID-19 infection or fulfilled local guidelines for COVID-19 testing but were COVID-19 negative on RT-PCR testing. The data items were the number of COVID-19 positive and negative patients with OD and total number of patients tested. Principal summary measures were pooled sensitivity, specificity, positive likelihood ratio (LR), negative LR and diagnostic odd ratios (DOR).

To investigate the estimated frequency of OD amongst COVID-19 patients, meta-analysis B included studies if they described the frequency of OD in COVID-19 positive patients and if smell tests were performed or if OD symptoms were explicitly asked in questionnaires or interviews. The latter criterion was chosen as OD symptoms were not routinely asked in early studies, which might explain the low frequency of OD reported in China. The data items were the number of COVID-19 positive patients with OD. The principal summary measure was the frequency of OD. Subgroup analyses was performed to investigate if the frequency differed between survey/questionnairereported OD and smell test-reported OD.

R Studio version 1.2.5042 [22] and R version 4.0.0 [23] were used for all statistical analyses. The packages meta [24] , mada [25] and dmetar [26] were used in the analyses. All data are presented as effect estimates with 95% confidence intervals in parenthesis. Heterogeneity amongst studies was tested using the Cochran's Q test and I 2 . A random effects model was used if I 2 > 50%. Forest plots were generated to summarise the results. Funnel plots and Egger tests were used to detect any publication bias.

A total of 498 studies were retrieved from PubMed. A total of 422 articles were excluded based on their titles and abstracts, and 57 of the remaining 76 articles were excluded for reasons as described in Fig. 1 . The remaining 19 articles were included in the meta-analysis.

A total of 1861 COVID-19 positive patients and 15,556 COVID-19 negative patients were included across the 19 studies as seen in Table 1 . The patients were from Canada, France, Germany, Hungary, Italy, Netherlands, Singapore, Spain, Turkey and the USA. All studies utilised RT-PCT as the COVID-19 diagnostic testing method. All studies described survey/questionnaire-reported OD.

With reference to Fig. 2 , patients with OD were more likely to test positive for COVID-19 (DOR 11.5 (8.01 to 16.5), positive LR 6.10 (4.47 to 8.32) and negative LR 0.58 (0.52 to 0.64)). The pooled sensitivity was 0.48 (0.40 to 0.56), and the pooled specificity was 0.93 (0.90 to 0.96) in using OD to predict . a Fifty-seven full-text articles were excluded: 49 did not include controls, 4 utilised inappropriate controls who were not swabbed for COVID-19 (3 studies used healthy asymptomatic individuals as controls and 1 study used historical influenza patients as controls), 2 utilised self-reported COVID testing results, 1 added in OD symptoms to their data collection sheet midway through the study and 1 did not explicitly ask for OD symptoms Curr Allergy Asthma Rep (2020) 20:76 

A total of 498 studies were retrieved from PubMed. A total of 422 articles were excluded based on their titles and abstracts, and 16 of the remaining 76 articles were excluded for reasons as described in Fig. 3 . The remaining 60 articles were included in the meta-analysis. 

With reference to Fig. 4 , the overall pooled frequency of OD amongst COVID-19 patients was 0.56 (0.47 to 0.64). There was significant heterogeneity amongst the 60 studies (I 2 = 98.8%, p < 0.001). Funnel plot is shown in Fig. 5b . Egger's test did not suggest the presence of publication bias (p = 0.204). Yan, 2020a [8] was not included in meta-analysis B of prevalence of OD as data likely overlaps with the other paper published by Yan [15] Excluded due to overlapping dataset. The largest series by Lechien [61] was included in the analyses % Excluded as COVID-19 testing and result was self-reported by patients and not verified @ Excluded as it is a follow-up study of the same dataset Table 2 summarises the risk of bias of all studies included in both meta-analyses A and B. Overall, the studies were of moderate to high risk of bias due to the lack of smell testing except for 6 studies, the presence of non-response bias using the questionnaire methodology or the inclusion of only particular groups of patients (e.g. only hospitalised patients, or only outpatients, or only those with mild-moderate disease).

The pooled frequency of OD in COVID-19 positive patients (17,401 patients, 60 studies) was 0.56 but differed between detection via validated smell testing (0.76) vs survey/questionnaire reports (0.53). This inconsistency of olfactory dysfunction between survey/questionnaire reports and validated smell tests has also been recognised in the literature [17, 18] . Moein et al. [19•] reported that 29% of their patients reported self-reported OD. However, validated smell tests on this same group of patients showed 58% to have anosmia or severe microsmia, with only 2% with normal olfactory function. Similarly, Vaira [9] reported 28.3% patients having s OD, while 98% had OD on validated smell tests. A significant number of patients with olfactory dysfunction do not report symptoms. Even within the realm of administered smell tests, cultural differences may result in inaccurate identification of smell dysfunction [96] . This might suggest that at least some of the variation in frequency rates of OD in COVID-19 may be attributed to differences in data collection methods.

Notwithstanding this, patient-reported OD as a symptom was highly specific (93%) but not sensitive (48%), for COVID-19 infection. The results of this metaanalysis further suggest that patients with reported OD were more likely to test positive for COVID-19 (diagnostic OR 11.5), with positive (6.10) and negative (0.58) LR. The presence of patient-reported OD can hence be used as an additional screening question to triage patients in determining the need for COVID-19 testing regardless of the presence of other concomitant upper respiratory symptoms. Whether smell test detected OD may serve as a more accurate screening tool remains to be investigated.

It is increasingly recognised that the COVID-19 infection can manifest as mild, moderate, severe or critical illness [97] . Yan et al. [15] reported that patients with OD may be associated with a milder clinical course. Izquierdo-Domínguez also reported that patients with more severe OD were less likely to be hospitalised and had a lower level of C-reactive protein [34] . However, patients who were intubated or deceased at the time of data collection could not be included in their study. If this were indeed true, the presence of OD might assist in Fig. 3 Flow diagram for metaanalysis B estimating the frequency of OD amongst COVID-19 patients. a Sixteen full-text articles were excluded: 9 did not specify if OD symptoms were explicitly asked, 5 likely used overlapping data and 2 utilised self-reported COVID testing results deciding the disposition of patients i.e. admission vs outpatient care. However, Moein et al. [19•] reported that there was no statistically significant difference in the mean UPSIT score between patients with mild, moderate or severe COVID-19. As such, this may be purely be due to recall bias, where patients with severe COVID-19 may be less cognizant of OD due to the presence of more bothersome symptoms such as dyspnoea. The prognostic value of OD in COVID-19 patients remains to be elucidated but is unlikely to override traditional, objective and actionable clinical measurements such as oxygen saturation, pulse rate and respiratory rate.

Various Otolaryngologic societies have issued statements addressing OD in COVID-19. On 21 March 2020, a press release was issued by ENT UK and the British Rhinological Society on Twitter, recommending that anosmia be added to the current symptom criteria used to trigger quarantine and that individuals with new-onset anosmia should self-isolate to reduce the risk of further transmission of COVID-19 [5] . This was largely based on anecdotal physician and media reports [98] . A similar statement was released by the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) on 22 March 2020 [99] , and a joint statement was released by the Chapter of Otorhinolaryngologists, College of Surgeons, Singapore, and the Society of Otolaryngology-Head and Neck Surgery, Singapore, on 17 April 2020 [100] . The US Centers for Disease Control and Prevention added "new loss of taste or smell" to the list of COVID-19 symptoms on 17 April 2020, while the World Health Organisation (WHO) has added the above as of 9 May 2020 [101] , albeit as a "less common symptom". The major limitation of the meta-analysis was the significant heterogeneity amongst included studies. Sources of heterogeneity include different inclusion criteria across studies (e.g. only hospitalised patients or only outpatients included, only mild-moderate illness included), different ways in which the OD questions were phrased and possibly the different RT-PCR sensitivities across different institutions around the world for detection of SARS-CoV-2 RNA. We were unable to perform a meta-analysis of the onset, duration and severity of OD due to the varied data collection protocols. As questionnaires were used in most of the studies, there might have been a strong recall bias in which patients who knew they were COVID-19 positive were more likely to report anosmia. Furthermore, it is impossible to survey intubated or deceased patients so findings may not be generalisable to the most severe of patients. Nevertheless, the clinical utility of patientreported OD in identifying COVID-19 infection amongst patients with mild-moderate symptoms remains important to facilitate cohorting and isolation, to minimise transmission.

Future research should utilise validated instruments for both survey/questionnaire (i.e. visual analogue scale [VAS] ) and smell testing of OD across various time points to quantify the onset and severity of OD and track its recovery. However, we recognise the inherent difficulties in conducting these tests amongst COVID-19 positive patients as it puts researchers at risk of infection. While it is important to correctly diagnose and classify the severity OD in order to study of the characteristics of hyposmia/ microsmia or anosmia amongst COVID-19 positive, from a public health perspective, it can be argued that the detection of self-reported OD via surveys of questionnaires is equally important in curbing the COVID-19 pandemic by assisting in identifying COVID-19 positive patients.

Patient-reported OD is a highly specific symptom of COVID-19 which should be included as part of the pre-test screening of suspect patients. 

Olfactory dysfunction in the COVID-19 outbreak

The loss of smell and taste in the COVID-19 outbreak -a tale of many countries

Anosmia-a clinical review

Furthering the understanding of olfaction, prevalence of loss of smell and risk factors: a populationbased survey (OLFACAT study)

Loss of sense of smell as marker of COVID-19 infection

Overuse of diagnostic tools and medications in acute rhinosinusitis in Spain: a populationbased study (the PROSINUS study)

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms

Objective evaluation of anosmia and ageusia in COVID-19 patients: single-center experience on 72 cases

Prevalence and duration of acute loss of smell or taste in COVID-19 patients

Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses

Transolfactory neuroinvasion by viruses threatens the human brain

Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv. 2020. A summary of the mechanisms of action of olfactory dysfunction in COVID-19

Expression of the SARS-CoV-2 entry proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium: identification of cell types and trends with age

Selfreported olfactory loss associates with outpatient clinical course in Covid-19

Real-time tracking of self-reported symptoms to predict potential COVID-19

Unawareness of olfactory dysfunction and its association with cognitive functioning in middle aged and old adults

Factors associated with inaccurate selfreporting of olfactory dysfunction in older US adults

This study demonstrates high incidence of olfactory dysfunction amongst patients with COVID-19. It also demonstrates the disparity between subjective and objective olfactory dysfunction. However, the reliability of the used smell test (UPSIT) was low since it was not

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement

RStudio: integrated development for R

R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing

How to perform a metaanalysis with R: a practical tutorial

mada: meta-analysis of diagnostic accuracy

dmetar: companion R package for the guide 'doing meta-analysis in R'

Utility of hyposmia and hypogeusia for the diagnosis of COVID-19

Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak

Anosmia and dysgeusia associated with SARS-CoV-2 infection: an age-matched case-control study

Acute olfactory loss is specific for Covid-19 at the emergency department

Loss of taste and smell as distinguishing symptoms of coronavirus disease 2019

Évaluation par RT-PCR du portage nasopharyngé du SARS-Cov-2 chez les personnels de santé symptomatiques suspects de COVID-19 dans un CHU de la banlieue parisienne

Predictive value of sudden olfactory loss in the diagnosis of COVID-19

Smell and taste dysfunctions in COVID-19 are associated with younger age in ambulatory settings -a multicenter crosssectional study

Selfreported anosmia and dysgeusia as key symptoms of coronavirus disease

Symptoms in health care workers during the COVID-19 epidemic. A cross-sectional survey

Prospective study in 355 patients with suspected COVID-19 infection. Value of cough, subjective hyposmia, and hypogeusia

Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary

Taste and smell impairment in COVID-19: an AAO-HNS anosmia reporting tool-based compar

Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands

Self-reported loss of smell and taste in SARS-CoV-2 patients: primary care data to guide future early detection strategies

The role of self-reported olfactory and gustatory dysfunction as a screening criterion for suspected COVID-19

Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster

Contribution of anosmia and dysgeusia for diagnostic of COVID-19 in outpatients

Olfactory and gustatory abnormalities in COVID-19 cases

A structural equation model to examine the clinical features of mild-to-moderate Covid-19: a multicenter Italian study

Acute-onset smell and taste disorders in the context of Covid-19: a pilot multicenter PCR-based case-control study

Olfactory and oral manifestations of COVID-19: sex-related symptoms-a potential pathway to early diagnosis

Prevalence and recovery from olfactory and gustatory dysfunctions in Covid-19 infection: a prospective

Olfactory and gustatory dysfunctions in COVID-19. First reports of Latin-American ethnic patients

Olfactory dysfunction in coronavirus disease 2019 patients: observational cohort study and systematic review

Smell and taste disorders during COVID-19 outbreak: a crosssectional study on 355 patients. Head Neck

Smell loss is a prognostic factor for lower severity of COVID-19

Symptomatology in head and neck district in coronavirus disease (COVID-19): a possible neuroinvasive action of SARS-CoV-2

Self-reported olfactory and taste disorders in patients With severe acute respiratory coronavirus 2 infection: a cross-sectional study

An online observational study of patients with olfactory and gustory alterations secondary to SARS-CoV-2 infection

Frequency and outcome of olfactory impairment and sinonasal involvement in hospitalized patients with COVID-19

A prospective clinical study of detailed neurological manifestations in patients with COVID-19

Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19

Features of anosmia in COVID-19

Loss of smell and taste in 2013 European patients with mild to moderate COVID-19

Time course of anosmia and dysgeusia in patients with mild SARS-CoV-2 infection

Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection

Olfactory and gustatory dysfunction in coronavirus disease 19 (COVID-19)

Olfactory and gustatory dysfunctions in 100 patients hospitalized for COVID-19: sex differences and recovery time in real-life

Prevalence of taste and smell dysfunction in coronavirus disease 2019

Asymptomatic infection and atypical manifestations of COVID-19: comparison of viral shedding duration

Persisting olfactory dysfunction in patients after recovering from COVID-19

Smell and taste alterations in COVID-19: a cross-sectional analysis of different cohorts

New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection

Olfactory and gustatory dysfunction as an early identifier of COVID-19 in adults and children: An International Multicenter Study

Acute smell and taste loss in outpatients: all infected with SARS-CoV-2?

Sex differences in the frequency of gastrointestinal symptoms and olfactory or taste disorders in 1942 nonhospitalized patients with coronavirus disease 2019 (COVID-19)

Olfactory dysfunction and sinonasal symptomatology in COVID-19: prevalence, severity, timing

Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection

Olfactory and taste disorders in healthcare workers with COVID-19 infection

Response system for and epidemiological features of COVID-19 in Gyeongsangnam-do Province in South Korea

Anosmia in COVID-19 patients

Objective olfactory evaluation of selfreported loss of smell in a case series of 86 COVID-19 patients

Remote psychophysical evaluation of olfactory and gustatory functions in early-stage coronavirus disease 2019 patients: the Bologna experience of 300 cases

Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study

Taste and smell dysfunction in COVID-19 patients

Self-reported symptoms of SARS-CoV-2 infection in a non-hospitalized population: results from the large Italian web-based EPICOVID19 cross-sectional survey

Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States

Smell and taste dysfunction during the COVID-19 outbreak: a preliminary report

Features of mild-to-moderate COVID-19 patients with dysphonia

Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019

Aggregate prevalence of chemosensory and sinonasal dysfunction in SARS-CoV-2 and related coronaviruses

Neurologic manifestations of hospitalized patients With coronavirus disease 2019 in Wuhan, China

Olfactory and gustatory outcomes in COVID-19: a prospective evaluation in nonhospitalized subjects

Accuracy of emergency department clinical findings for diagnosis of coronavirus disease 2019

Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry

Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study

Alterations in smell or taste-classic coronavirus disease 2019? Clin Infect Dis

Psychophysical olfactory testing in COVID-19: is smell function really impaired in nearly all patients?

Clinical-pathological correlation of the pathophysiology and mechanism of action of COVID-19 -a primer for clinicians

Sniffing out the evidence for olfactory symptoms as a clinical feature of COVID-19: a systematic scoping review

AAO-HNS: anosmia, hyposmia, and dysgeusia symptoms of coronavirus disease

Joint statement of the Chapter of Otorhinolaryngologists College of Surgeons Singapore and the Society of Otolaryngology-Head and Neck Surgery Singapore. Acute olfactory and gustatory dysfunction as a symptom of COVID-19 infection

World Health Organisation. Coronavirus -symptoms

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Authors' Contributions Khang Wen Pang and Jeremy Chee contributed equally to this paper and are co-first authors. Somasundaram Subramaniam and Chew Lip Ng contributed equally to this paper and are co-last authors. Chew Lip Ng and Somasundaram Subramaniam conceptualised the study. Khang Wen Pang and Jeremy Chee designed the study. Khang Wen Pang and Jeremy Chee screened titles and abstracts for inclusion. Khang Wen Pang and Jeremy Chee extracted and analysed data. Khang Wen Pang, Jeremy Chee, Chew Lip Ng and Somasundaram Subramaniam helped interpret the findings from the meta-analyses and interpretation from a clinical viewpoint. Khang Wen Pang and Jeremy Chee wrote the first draft, which all authors revised for critical content. All authors approved the final manuscript. Khang Wen Pang and Jeremy Chee are the guarantors. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.Data Availability The authors will share data upon reasonable request.

Conflict of Interest The authors declare no conflicts of interest relevant to this manuscript.

This article does not contain any studies with human or animal subjects performed by any of the authors.Ethics Approval Not required for this study.Consent to Participate Not applicable.

Code Availability The authors will share the full statistical code upon reasonable request.

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance